Recruiting Vasculitis Studies in Denver
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy....
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis....
About Vasculitis Clinical Trials in Denver
Vasculitis refers to a group of disorders that involve inflammation of blood vessels, which can restrict blood flow and damage organs. Types include ANCA-associated vasculitis, giant cell arteritis, and Takayasu arteritis. Treatment typically involves corticosteroids and immunosuppressive medications.
There are currently 2 vasculitis clinical trials recruiting participants in Denver, COLORADO. These studies are seeking a combined 205 participants. Research is being sponsored by GlaxoSmithKline, NS Pharma, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.
Vasculitis Clinical Trials in Denver — FAQ
Are there vasculitis clinical trials in Denver?
Yes, there are 2 vasculitis clinical trials currently recruiting in Denver, COLORADO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Denver?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Denver research site will contact you about next steps.
Are clinical trials in Denver free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Denver studies also compensate for your time and travel.
What vasculitis treatments are being tested?
The 2 active trials in Denver are testing new therapies including novel drugs, biologics, and treatment approaches for vasculitis.
Data updated March 2, 2026 from ClinicalTrials.gov